Cite
HARVARD Citation
Weberpals, J. et al. (n.d.). 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations. International journal of gynecological cancer. pp. A2-A3. [Online].